Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam-nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.
|Number of pages||5|
|Journal||Clinical infectious diseases : an official publication of the Infectious Diseases Society of America|
|Publication status||Published - 27-07-2020|
All Science Journal Classification (ASJC) codes
- Microbiology (medical)
- Infectious Diseases